Chromosome Chaos Unmasks 81 New Targets in the Hardest Breast Cancer to Treat

Basal-like breast cancer is the most aggressive form of the disease and the hardest to drug. A new study shows its defining feature — mangled chromosomes — is not random wreckage but a selection engine, and the experiment turned up 81 fresh genes to attack.

Cancer genomes are notoriously messy. Tumor cells pile up extra copies of some chromosomes and lose others entirely, a condition called aneuploidy. For decades, researchers have known aneuploidy is common in cancer, but they have not been able to tell which chromosome abnormalities cause damage and which are just passengers along for the ride. The problem is scale: the chromosomes of a basal-like breast tumor can be riddled with hundreds of gains and losses at once, making it nearly impossible to isolate a single cause.

Key finding: By testing thousands of genes inside living tumors, the team found that aneuploidy does more than wreck cells — it actively selects for specific driver genes. The method uncovered roughly 81 new genes that fuel basal-like breast cancer, including a standout oncogene called PLGRKT.

Making the messy tractable

Instead of sequencing tumors and guessing, the researchers engineered the chromosome changes directly, one at a time, and watched which ones pushed the tumor forward. It was a controlled dissection of the genome's chaos. The genes that mattered kept appearing, over and over, wherever the experiment was run.

The standout: PLGRKT

Among the genes that rose to the top, PLGRKT stood out as a particularly potent driver. Sited on chromosome 9p, it helps cancer cells survive deep inside a tumor, where oxygen is scarce, by switching to a different metabolic process to generate energy without it. Tumors that had acquired PLGRKT were notably hardier, and the gene points to a clear new target: drugs that block this metabolic switch could starve the deepest, most resistant part of the tumor.

Why basal-like is so hard to treat

Basal-like, often called triple-negative, breast cancer is named for what it lacks — receptors for the hormones and proteins that modern drugs exploit. Without those handles, traditional targeted therapies have little to grab onto. Each new driver gene, by contrast, is a handle: a molecular lever a future drug could pull. Ninety driver genes identified and roughly 81 fresh treatment targets means the field is moving from "we have no options" toward "here are the options we have not yet tried."

The headline takeaway.

The hallmark of an aggressive breast tumor is genomic disorder. The surprising answer from this study is that the disorder is doing a job — sorting the worst genes to the top — and now those genes have names.